Novartis targeted radiation therapy gets FDA nod for advanced prostate cancer March 23, 2022 Auto Bot BioPharma, Clinical Trial, FDA, Legal, Novartis, Pharma, Pluvicto, prostate cancer, Radiation Oncology 0 The FDA approved Pluvicto, a Novartis radiopharmaceutical, as a new treatment option for advanced prostate cancer. Novartis added the therapy via its $2.1 billion acquisition of Endocyte four years ago.